The Hindu Business Line : Dr Reddy’s new pill to revitalise betapharm

Stung by the impact of its German subsidiary, betapharm’s, blues, Dr Reddy’s Laboratories Ltd is now busy preparing a pill to return betapharm to the pink of health.

The stated reason for the Hyderabad-based company’s poor show in the second quarter of current fiscal with 37 per cent and 5 per cent dip in revenue and net profit respectively was the poor performance of betapharm due to supply constraints.

Further, the firm is also facing pricing pressure in Germany due to certain reforms taken up by German Government and increasing influence of insurance companies on pricing, according to Mr K. Satish Reddy, Managing Director, Dr Reddy’s.

The production at betapharm ran into rough weather as the main supplier, Salatus, failed to maintain schedules. “We are adopting a multi-pronged strategy to put betapharm back on track,” Mr Reddy told Business Line here.

Shifting key product manufacturing to India, adopting different cost structures and ensuring steady supplies from other suppliers would be part of the strategy, he explained.

About 20 products had been transferred out of Salutus so far including six products to India. “The shipments of two products have just begun from India,” he said.

The shifting of manufacturing base to India would be a profitable proposition for Dr Reddy’s as it is setting up two SEZs for active pharmaceutical ingredients (APIs) and formulations at Hyderabad and Visakhapatnam respectively with an investment of over $50 million, Mr Reddy said.

In addition, the firm plans to improve its sales in Germany which fell to Rs 190 crore in the second quarter of current fiscal from Rs 260 crore in the corresponding period of last fiscal through strengthening its competitive cost position and leveraging relationships with insurance companies by entering into rebate contracts and securing tenders. “We have started participating in major tenders. The focus is on driving demand through rebate contracts from large insurance companies in Germany,” he added.

Notwithstanding these measures, betapharm will continue to brew trouble for its parent at least for next 18 months. While improvement in betapharm’s performance would be “visible” from next quarter, the company would make profit only by FY09, according to Mr G.V. Prasad, CEO, Dr Reddy’s.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Arabian sea sees intense activity as ‘low’ grows

DoT pushes for auction of GSM spectrum

Cheaper non-food items keep inflation rate static

Rupee appreciation has little impact on L&T

Dr Reddy’s new pill to revitalise betapharm

L&T net jumps 73% buoyed by growth in sales

Tata Steel posts 8% profit growth in Q2

Scale-up of business segments drives ITC Q2 net 13% higher

TCS opening new unit in S. Africa

Infosys rejigs biz units to be market-ready

High prices take the sheen off gold

Sensex gains 472 points as PN norms set in

This recovery rally belongs to domestic institutions

Too early to assess impact: Chidambaram

Sun Pharma confident of closing Taro deal

Syndicate Bank net up 11% on better yield on loans